Cerapedics to Participate in Canaccord Genuity's Musculoskeletal Conference

Company will provide update on U.S. commercial release of i-FACTOR™ Peptide Enhanced Bone Graft.

23 Feb, 2016, 08:30 ET from Cerapedics

WESTMINSTER, Colo., Feb. 23, 2016 /PRNewswire/ -- Cerapedics, a privately-held orthobiologics company, today announced the company will participate in Canaccord Genuity's Musculoskeletal Conference to be held March 1, 2016 at the Orlando Hyatt Regency.

Glen Kashuba, CEO of Cerapedics, will provide an update on the U.S. commercial release of i-FACTOR™ Peptide Enhanced Bone Graft, which was recently approved by the Food and Drug Administration for use in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease.

For more information about the meeting visit http://www.canaccordgenuity.com/en/cm/News-Events/Events/.

About Cerapedics

Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found at www.cerapedics.com.

Media contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

SOURCE Cerapedics



RELATED LINKS

http://www.cerapedics.com